Meningococcal disease is a global problem responsible for significant morbidity and mortality particularly in sub-Saharan Africa. Advances in immunisation have made a substantial difference to the incidence of meningococcal disease in the UK but cases still occur, because we do not yet have vaccines to prevent all serogroups. For this reason it is important that health professionals understand this disease and the different serogroups, vaccines and target groups to ensure that all those who should be are being protected from this harmful pathogen, and that symptoms of disease are recognised and treated without delay.
Primary Health Care. 23, 2, 32-36. doi: 10.7748/phc2013.03.23.2.32.e702
Correspondence Conflict of interestNone declared
Peer reviewThis article has been subject to double blind peer review
Received: 25 September 2012
Accepted: 30 October 2012
or
Alternatively, you can purchase access to this article for the next seven days. Buy now
Are you a student? Our student subscription has content especially for you.
Find out more